Ferguson J, Burns C J, Regourd E, Costanzo A
National Institute for Biological Standards and Control (NIBSC), Blanche Lane, South Mimms, Potters Bar, EN6 3QG, United Kingdom.
European Directorate for the Quality of Medicines & Healthcare (EDQM), Department of Biological Standardisation, OMCL Network & HealthCare (DBO), Council of Europe, Strasbourg, France.
Pharmeur Bio Sci Notes. 2019;2019:27-33.
The European Pharmacopoeia (Ph. Eur.) Biological Reference Preparation (BRP) for erythropoietin (EPO) is used as a working standard for potency determination of EPO preparations by bioassay as prescribed in Ph. Eur. monograph 1316 'Erythropoietin concentrated solution'. BRP batch 4 (BRP4) was calibrated in 2014 and its stocks are depleted. The European Directorate for the Quality of Medicines and HealthCare (EDQM) thus endorsed a project (BSP147) to calibrate a replacement batch in International Units against the 3rd WHO International Standard (IS) for erythropoietin, recombinant, for bioassay (11/170). The amount of material contained in the vial of BRP4 greatly exceeded the amount needed for one bioassay, sometimes leading to considerable waste. It was thus decided to prepare a candidate material with a lower EPO content. The collaborative study involved eight laboratories in Europe, the USA and Australia. Based on the outcome of the study, the Ph. Eur. Commission adopted the proposed standard as Erythropoietin BRP batch 5 in June 2018 for use as a reference preparation solely for the polycythaemic and normocythaemic mouse bioassays, with an assigned potency of 2000 IU/ampoule. Furthermore, the potency of BRP batch 4 was confirmed during the study thus warranting a good continuity of the International Unit.
欧洲药典(Ph. Eur.)中促红细胞生成素(EPO)的生物参考制剂(BRP)用作按照Ph. Eur. 各论1316“促红细胞生成素浓溶液”中规定的生物测定法测定EPO制剂效价的工作标准品。BRP第4批(BRP4)于2014年进行了校准,其库存已耗尽。因此,欧洲药品质量管理局(EDQM)批准了一个项目(BSP147),以根据世界卫生组织促红细胞生成素第3个生物测定国际标准品(IS)(11/170),以国际单位校准一批替代品。BRP4安瓿中所含物质的量大大超过一次生物测定所需的量,有时会导致大量浪费。因此决定制备一种EPO含量较低的候选材料。合作研究涉及欧洲、美国和澳大利亚的8个实验室。根据研究结果,Ph. Eur. 委员会于2018年6月采用了提议的标准品作为促红细胞生成素BRP第5批,仅用于红细胞增多症和正常红细胞血症小鼠生物测定,指定效价为2000 IU/安瓿。此外,在研究期间确认了BRP第4批的效价,从而保证了国际单位的良好连续性。